ReviewFrontiers in pharmacology2025
Recent advances in natural polysaccharides for type 2 diabetes management: sources, structural characteristics, and mechanistic insights.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Polysaccharide fromMetabolites · 2026Article
- Molecular mechanisms and structure-activity relationships of natural polysaccharides in ameliorating type 2 diabetes mellitus: a comprehensive review.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global prevalence of type 2 diabetes mellitus (T2DM) continues to rise, posing significant challenges for existing therapeutic strategies, which are often limited by poor bioavailability, high cost, and adverse effects. Natural polysaccharides have emerged as promising metabolites due to their broad sources, favorable safety profiles, and stable efficacy. This review systematically summarizes the sources, structural characteristics, and mechanisms of action of natural polysaccharides with anti-T2DM activity, with a particular focus on their multi-target regulatory effects in mitigating T2DM and its complications. By integrating structural diversity-such as molecular weight, glycosidic linkage patterns, and branching architecture-with functional outcomes across key pathogenic pathways including insulin resistance, inflammation, oxidative stress, gut microbiota dysbiosis, and mitochondrial dysfunction, this work elucidates fundamental structure-activity relationships. The review not only bridges existing knowledge gaps in multi-mechanistic integration but also provides a conceptual framework for the structure-based development of polysaccharide-based therapeutics against T2DM, highlighting future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.